Factors Contributing to Fentanyl Pharmacokinetic Variability among Diagnostically Diverse Critically-Ill Children

Fanuel T. Hagos, PhD[*,1], **Christopher M. Horvat, MD, MHA**[*,2,3], **Alicia K. Au, MD, MS**[2,3], **Yvette Conley, PhD, RN**[4,5], **Patrick M. Kochanek, MD**[2,3], **Robert S. B. Clark, MD**[2,3], **Philip E. Empey, PharmD, PhD**[3,6]

[1]Center for Clinical Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, PA

[2]Department of Critical Care Medicine, University of Pittsburgh School of Medicine and Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA

[3]Safar Center for Resuscitation Research, University of Pittsburgh, Pittsburgh, PA

[4]Department of Health Promotion and Development, University of Pittsburgh School of Nursing, Pittsburgh, PA

[5]Department of Human Genetics, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA

[6]Division of Pharmacy and Therapeutics, University of Pittsburgh School of Pharmacy, Pittsburgh, PA

Abstract

Objective: To characterize the population pharmacokinetics (PK) of fentanyl and identify factors that contribute to exposure variability in critically ill pediatric patients.

Design: Single-center, retrospective cohort study using electronic record data and remnant blood samples.

Setting: Mixed medical/surgical intensive care unit at a quaternary children's hospital.

Patients: Children with a predicted intensive care unit (ICU) length of stay of at least 3 days and presence of an indwelling central venous or arterial line.

Methods: Serum fentanyl measurements were performed for 278 unique remnant samples from 66 patients. Both one and two-compartment models were evaluated to describe fentanyl disposition. Covariates were introduced into the model in a forward/backward, stepwise approach and included age, sex, race, weight, cytochrome P450 3A5 (CYP3A5) genotype, and the presence of CYP3A4 or CYP3A5 inducers or inhibitors. Simulations were performed using the successful model to depict the influence of inducers on fentanyl concentrations.

Corresponding Author: Christopher M. Horvat, 4401 Penn Ave, Faculty Pavilion Suite 2000, Pittsburgh, PA 1524. Christopher.horvat@chp.edu. Phone: (412) 692-5298. Fax: (412) 692-6076.
[*]These authors contributed equally to this manuscript.

Main Results: A two-compartment base model best described the data. There was good agreement between observed and predicted concentrations in the final model. The typical fentanyl clearance for 70kg (reference weight) and 20.1kg (median weight) patients were 34.6 L h^{-1} and 13.6 L h^{-1} respectively. The magnitude of the unexplained random inter-individual variability was high for both clearance (60.7%) and V1(107.2%). Co-administration of the known CYP3A4/5 inducers fosphenytoin and/or phenobarbital was associated with significantly increased fentanyl clearance. Simulations demonstrate the effect of inducer administration was most pronounced following discontinuation of a fentanyl infusion.

Conclusions: We demonstrate the feasibility and utility of using electronic record data and remnant blood samples to successfully construct population PK models for a heterogeneous cohort of critically-ill children. A clinically relevant effect of concomitant CYP3A4/5 inducers was identified. Scaling this population PK approach is necessary to craft precision approaches to fentanyl administration for critically-ill children.

Introduction

Strategies for selecting a specific sedative-analgesic drug and dose in the pediatric intensive care unit (PICU) are largely rooted in empiricism, guided by institutional standards, individual experience, and heuristic estimates of what a patient will require for adequate comfort and safety. A large study comparing a sedation protocol versus usual sedation in children with respiratory failure did not demonstrate any difference in the primary outcome, duration of mechanical ventilation.[1] The relationship between wakefulness, pain, agitation, iatrogenic drug dependence, and adequate sedation-analgesia in children is variable, influenced largely by pharmacokinetics (PK) and pharmacodynamics (PD). Unfortunately, these remain poorly characterized for most commonly used drugs in the PICU.

Fentanyl is a highly lipid-soluble opioid frequently favored in the PICU for continuous sedation-analgesia owing to its observed, relatively neutral hemodynamic effects.[2] Characterizing fentanyl PK and factors associated with variable dose requirements among critically-ill children is challenging due to the dense sampling strategy required by traditional PK studies being obviated by caregiver stress and concern for iatrogenic anemia in the setting of critical illness. Several small studies have reported a range of PK parameters in children admitted to the PICU, though the limited cohort sizes do not sufficiently account for the patient and clinical heterogeneity inherent in this population.[3] The largest fentanyl PK study in children used population-level modeling methods to characterize PK parameters from sparse samples; however, this study was restricted to a relatively homogenous cardiac intensive care unit population with a median age less than 1 year old.[4]

Conventionally, fentanyl is dosed in micrograms per kilogram (μg/kg) in pediatrics, with standard bolus doses ranging widely from approximately 1 μg/kg to 10 μg/kg and infusions commonly initiated at 0.5 to 2 μg/kg/hour. The therapeutic window of fentanyl has been reported to be relatively narrow, with serum concentrations associated with mild analgesia reported to be 0.6 ng/ml and substantial analgesia reported at concentrations ranging from 1.2 to 3 ng/ml among adults.[5,6] Fentanyl dose response among critically-ill children is reported to be highly variable and standard approaches are to administer doses until a

desired clinical effect is achieved.[7,8] At least part of this variability in response is related to fentanyl being metabolized predominantly by the hepatic cytochrome P450 enzyme CYP3A4, the activity of which demonstrates high inter-individual variability and evolves with age.[3,9] The objective of this study was to construct a population PK model for fentanyl and to identify demographic and clinical covariates that affect the PK parameters of fentanyl in a clinically diverse cohort of critically-ill children. Modeling fentanyl PK among children in the PICU is a necessary step towards more individualized dosing strategies, with the ultimate goal of reducing episodes of inadequate sedation-analgesia and optimizing the safety of these patients.

Methods

Study Design and Population

A retrospective cohort study was undertaken involving patients admitted to the PICU at our quaternary children's hospital. Approval was granted by the University of Pittsburgh Institutional Review Board. Fentanyl is administered intravenously as a continuous infusion and/or as an intermittent bolus. All aspects of the administration of fentanyl including doses of both the infusion and boluses were determined by the clinical staff. Serum samples and DNA were previously banked as part of a previous cohort study of randomly enrolled PICU patients with inclusion criteria that included predicted PICU length of stay (LOS) 3 days, presence of an indwelling central venous or arterial line for blood sampling, obtainment of informed consent from the parent or legal guardian and were otherwise unrestricted. Serum samples and blood pellets were stored at −80°C. Each serum sample used for analyses contained at least 100 μL. Samples were collected at unspecified times that were convenient for nurses responsible for collection, without an *a priori* plan to use the samples for PK analyses and independent of drug administration. DNA was extracted using the Qiamp DNA extraction kit (Qiagen Inc; Valencia, CA).

Demographics and clinical characteristics were extracted from an electronic health record (EHR) data warehouse using the business intelligence platform SAP BusinessObjects (SAP, Waldorf, Germany). The primary admission diagnosis for each patient was categorized as neurologic, respiratory, sepsis, gastrointestinal disease including hepatic and bowel transplant recipients, or other. Discrete fentanyl dose amount and administration timing were determined from the patient medication administration record. Biomarker levels of interest were extracted from the data warehouse and included alanine and aspartate aminotransferase, serum albumin, and creatinine. All administered medications were reviewed and, in addition to fentanyl, medications of interest selected for inclusion in the models were previously reported CYP450 enzyme inducers fosphenytoin, phenytoin, and phenobarbital and the inhibitor fluconazole, provided the inhibitor/inducer had been administered for at least 48 hours prior to administration of fentanyl.

Drug Concentration Assessment and Population Pharmacokinetic Analysis

Serum fentanyl concentrations were measured using a sensitive and specific validated LC-MS/MS method that had been previously described.[10] Measured levels above the limit of quantification were excluded from the study. Levels within 15% of the lower limit of

quantification were included in the primary analysis. A separate sensitivity analysis was performed excluding levels below the lower limit of quantification. NONMEM 7.3 software (ICON, Ellicot City, MD) was used to perform the nonlinear mixed effects analysis. The software tools and packages Pirana, Perl-speaks-NONMEM (PsN), Xpose4, Xpose (Uppsala University, Pharmacometrics Research Group, Uppsala, Sweden), Excel (Microsoft Corp., Redding, WA), R version 3.3.3 (R foundation for Statistical Computing, Vienna, Austria) and OpenRefine (version 2.7) were used to facilitate data set preparation, analysis, bootstrap analysis, visual predictive check (VPC) analysis and preparation of graphical outputs.[3,11–13] Parameters were estimated using the first-order conditional estimation with interaction (FOCE-I) method. An exponential model, $P_{ij} = TV(P_j)exp(\eta_{ij})$, was used to describe the variability between individual parameters where η_{ij} is the random effect of the ith individual and the jth parameter which assumed to be normally distributed with a mean of 0 and variance of ω^2.

The residual variability was modelled using the additive model after log-transformation of both sides. Although previous studies have reported that fentanyl follows two-compartment disposition model, a one-compartment model was also explored.[4,14] The effect of patient weight on clearance and volume of distribution terms were incorporated in the base model by allometric scaling using $P_i = P_{STD}* (W_i/W_{STD})^{PWR}$ where P_i and W_i are the PK parameters and weight of the ith individual, respectively. W_{STD} is the reference weight, set to 70 kg for these analyses, and P_{STD} is the PK parameter of the individual of the reference weight. The PWR exponent was fixed at 0.75 for clearance terms and 1 for volume terms.

Age, race, sex, CYP3A5 rs28365094 genotype, and concomitant administration of CYP3A4/5 inducers or inhibitors were investigated for their effect on clearance. On the basis of a previously reported association with a *CYP3A5* single nucleotide polymorphism at rs28365094, covariate evaluation included attempting to model dichotomized genotype, TT versus CT+CC, at this locus.[15] Race was dichotomized into white and non-white and the use of a CYP3A4/5 inducer or inhibitor was dichotomized into present or absent. Power models were used to describe the relationship between covariates and the typical value of clearance. A sigmoidal maturation function ($CL=(CL_{typical-value}*WT/70)^{0.75}*(Age^h/Age_{50}^h + Age^h)$) was also attempted to describe the effect of age using postnatal age since gestational age was not available. All continuous variables were normalized by the median value of the covariate in the cohort. Covariates were added to a model by multiplicative relationship.

Covariate selection was performed using a stepwise approach. The process began with forward addition, in which covariates are added one at a time and considered significant if the covariate contributes to greater than 3.841 reduction in the objective function ($\alpha=0.05$, 1 degree of freedom) when added to the previous model. The covariate that improved the model the most is added first and is kept in the model if it fulfills the significance test. The resulting model serves as the base mode for the addition of the next covariate step. step These steps were repeated until there were no significant remaining covariates. A backward elimination step was then performed, in which a covariate was considered significant if it contributed to greater than a 6.635 magnitude increase in objective function ($\alpha=0.01$, 1 degree of freedom) when removed from the previous model. These steps were repeated until

there were no non-significant covariates remaining. Assessments of the fit of the PK models were performed by visual inspection of diagnostic plots, successful minimization, visual predictive checks, and changes in objective function values. The stability of the final model and the precision of the parameter estimates were internally validated by bootstrapping in PsN. One thousand replicates were generated by random sampling with replacement from the original dataset. The nonparametric statistics (i.e., median and 95% CI) of the parameter estimates generated by bootstrap were compared to the point estimates obtained from the model.

To demonstrate the effect of concomitant administration of CYP3A4/5 inducers, concentration-time profiles of fentanyl were simulated for 200 patients with the median weight of 22kg in the presence and absence of preceding 48-hours of inducer administration. For this simulation, it was assumed that induction of fentanyl metabolism was in effect at the initiation of fentanyl administration (i.e., subjects who received a CYP3A4/5 inducer for at least 48 hours prior to the start of a fentanyl infusion). It was also assumed that administration of fentanyl began with a bolus dose (1 μg/kg), followed by initiation of an infusion (1 μg/kg/hr) 30 minutes afterwards. Two subsequent boluses (1 μg/kg) were also simulated, at 2 and 9 hours after initiation of the infusion, and the infusion rate (1 μg/kg/hr) remained constant and was continued for 48 hours after receipt of the second bolus, to simulate the steady state. Finally, the trajectories of fentanyl levels were examined for an additional 24 hours following cessation of the infusion to observe the distribution and elimination phases in the presence and absence of an inducer. Concentration-time plots of patients in presence or absence of CYP3A4/5 inducers were created for visual comparison of the effect of inducers.

Results

A total of 278 samples from 66 patients were used for PK analysis. Baseline demographic and clinical characteristics of the study participants are summarized in Table 1. In 60/66 of the subjects, samples were collected before, during and after continuous infusion. In 6 subjects, all samples were collected when the subjects had received one or more boluses only and no infusion prior to sample collection. One sample with levels above the upper limit of quantification of the assay was excluded from the analysis. Fourteen of the 278 samples were within 15% of the assay's lower limit of quantification and were included in the analysis.

A two-compartment model with linear elimination, and allometrically-scaled weight effects on CL, Q, V1 and V2, was selected as the base model. The final parameter estimates of the model are in Table 2. A sensitivity analysis excluding samples below the lower limit of quantification did not result in substantially different estimated parameters (Supplemental Table 1). Retaining the samples resulted in improved model minimization and covariance completion. The typical population PK parameters (estimates [bootstrapped 95% confidence interval]) relative to the reference patient (70 kg and no concomitant administration of CYP3A4/5 inducer or inhibitor) are reported. The typical CL of fentanyl for a 70kg subject without the presence of a CYP3A4/5 inducer was 34.6 L h^{-1}. For a subjecting weighing 20.1kg, which is the median weigh of the study population, the typical CL was 13.6 L h^{-1}.

No enrolled patient received concomitant CYP3A4/5 inhibitor and inducer medications. Among the covariates tested, only the presence or absence of a concomitantly administered CYP3A4/5 inducer was found to have a significant effect on CL increasing CL value by mean factor of 1.54. The assessed genotype did not significantly affect CL. Age and weight were highly correlated (Supplemental Figure S1) and including age did not improve the model. Assessment of percentage of relative standard errors (RSE) indicated that clearance, volume of distribution of the central compartment, inter-compartmental clearance, volume of distribution of the peripheral compartment, effect of inducers and residual variability were estimated with good precision (RSE values of these parameters were less than 30%). Interindividual variability of both clearance and volume of distribution of the central compartments were estimated with moderate precision with RSE values of 38.2% and 43.1%, respectively. The magnitude of the unexplained random interindividual variability (% CV) remained high for both CL and V1 at 60.7% and 107.2%, respectively. For all parameters, the median bootstrapped parameter estimates were comparable to the point estimates from the original datasets showing the model was robust and described the data well. ETA shrinkage, the shrinkage of inter-subject variability, was 10.3% for CL and 50% for V1. Epsilon shrinkage, the shrinkage of the proportional intra-subject variability, was 10.8%.

The goodness-of-fit plots are presented in Figure 1. The population predicted versus observed concentration (Figure 1A) and the individual predicted versus observed concentration (Figure 1B) plots indicate a good agreement between observed and predicted concentration along with sufficiently symmetric distribution and random scatter of data points around the line of unity. Slight biases at the low end of the population plot and high end of the individual plot were observed. This was also observed in the individual weighted residual (IWRES) vs. individual predicted concentration plot (Supplemental Figure S2). The conditional weighted residuals plotted across population predicted concentration (Figure 1C) and over time (Figure 1D) similarly show symmetrical distribution around the line of zero and that the model described the data well. No trends were observed over time, and a slight bias was observed at the lower value of population predicted concentrations. The normal distribution assumption of ETA1 (inter-individual variability for CL) and ETA2 (inter-individual variability for V1) were valid (Supplemental Figure S3). The VPCs also indicate that the model adequately describes both the data dynamics and dispersion (Figure 2). There was generally good agreement between observed and simulated serum concentrations across time with the observed fentanyl plasma concentrations contained within the simulated 95% confidence interval.

Figure 3 shows the simulated effect of concomitant administration of a CYP3A4/5 inducer on fentanyl concentration for 200 patients. As CL increased in the presence of a concomitant inducer, the plasma levels of fentanyl are generally lower as shown in the concentration-time plot (Figure 3A). The effect was most pronounced following discontinuation of the fentanyl infusion. Figure 3B shows that the Css was also significantly lower ($P<0.0001$) in patients receiving inducers although variability remains high.

Discussion

The use of fentanyl is ubiquitous in pediatric critical care, yet factors associated with variable fentanyl dose requirements have not been well-characterized in this heterogeneous patient population, in part due to frequent but impractical sampling requirements for constructing traditional PK models. We leveraged EHR data, sparse remnant blood samples collected at random times, and population PK modeling to successfully describe fentanyl dose-concentration-time in critically ill children. To the best of our knowledge, this study includes the largest cohort of diagnostically diverse, critically-ill children enrolled for building a PK model of fentanyl. Clearance was 13.6 L h^{-1} for a 20.1kg – a median weight for the population in the current study – subject which is comparable with findings from other critically-ill pediatric populations.[3,4] Concomitant administration of CYP3A4/5 inducers significantly affected clearance of fentanyl, though the relatively large magnitude of unexplained interindividual variability in both clearance and volume of distribution indicate that other, non-modeled factors were influencing dose-requirements in this heterogeneous population. The findings of this study demonstrate the feasibility of population PK modeling as a foundational element towards more precise prescribing of fentanyl in the PICU.

A recent systematic review of PK parameters for fentanyl and its derivatives in children identified 14 studies with published CL values ranging from 0.41 to 68.5 mL/min/kg and cohort sizes ranging from 1 to 130 included patients.[3] Our selection of a two-compartment model was compatible with other studies examining fentanyl PK in children. The largest study used a population PK approach to characterize PK parameters for children admitted to a cardiac ICU, had a median age of 5.9 months, and reported a CL of 39.6 L/hr, which is comparable with the findings of the present work (34.6 L/hr).[4] We opted for a two-compartment model of fentanyl, in alignment with other fentanyl PK studies, though some studies have proposed a three-compartment model as more representative of fentanyl distribution.[4,14,16–19] A three-compartment model has been proposed to represent initial fentanyl exposure in well-perfused end-organs, with subsequent redistribution to skeletal muscle, followed by slower distribution to adipose tissue. Such a model is supported by preclinical data collected with dense sampling strategies and higher doses than conventionally used in clinical settings, facilitating detection of a third slope of elimination. [20] The sparse sampling strategy of the population PK modeling approach may obscure detection of this third compartment, instead offering the advantage of pragmatic sample collection and larger cohort sizes while still yielding clinically relevant models.

We chose to include weight in the base model given the weight-normalized dosing common in pediatrics. Age and weight are highly correlated and much of the influence of age on fentanyl PK can be accounted for with weight; however, our model does not account for the influence of age exclusive of weight on the PK parameters. The previously observed relationship between fentanyl PK and age has been hypothesized to be related to differences in volume of distribution given the lower concentrations observed in infants vs. older patients soon after initiation of an infusion.[16] Mean body fat in a full term neonate is 12%, increases to approximately 30% by 1 year of age, and subsequently decreases, though the obesity epidemic in many developed nations has altered the historically observed decline of

body mass index (BMI) in older children and adolescents.[21–23] Fentanyl's high lipid solubility is expected to interact significantly with body fat composition and total body water content. A population PK study of fentanyl among critically-ill adult patients identified liver disease, congestive heart failure and weight as factors strongly influencing pharmacokinetics.[14] The median and range of weight in our cohort was 20.1 kg (4.1 – 117.4 kg), which is representative of patient heterogeneity that is commonplace in the PICU and relatively unique to this arena of medicine. A recent review noted only a weak association between weight and fentanyl clearance in preterm and term neonates and acknowledged a lack of data in older children.[3] A relationship between age, adiposity and fentanyl requirements has some supporting evidence and strong biologic plausibility, indicating the need for larger population PK cohorts with sufficient power to control for body fat, body water, and muscle mass.

Fentanyl is a high-extraction drug with clearance largely determined by hepatic blood flow. [24] This property is thought to reduce the likelihood of drug-drug interactions given the expected marginal influence of the major hepatic drug metabolism enzymes, CYP3A4 and 5. [25] However, fentanyl's extraction ratio has only been studied in healthy volunteers, making drug clearance in the context of critical illness and with multiple co-administered medications uncertain.[26] Fosphenytoin, phenytoin and phenobarbital are commonly used antiepileptic medications in pediatric critical care. These drugs are also established inducers of hepatic cytochrome P450 enzymes. CYP3A4 is involved in the metabolism of approximately 50% of all marketed medications and CYP3A4/5 enzymes play the major role in fentanyl metabolism.[3,9,27–31] Xenobiotic response elements exist in regions of *CYP* genes and, when bound by a ligand, activate gene transcription.[31] Ligand-bound forms of pregnane X receptor and closely-related constitutive androstane receptor each form a heterodimer with retinoid X receptor, ultimately binding xenobiotic response elements in promoter regions and inducing transcription.[31–33] Both (fos)phenytoin and barbituates are combined pregnane X and constitutive androstane receptor activators, inducing CYP3A4/5. [31,34–37]

Though this inducer effect has been mechanistically well-defined, the clinical impact among intensive care patients has not been studied and the time course of clinical drug-inducer effects is unknown. The effect of drug metabolism enzyme inducers on fentanyl clearance and the time course of these inducer effects has only been evaluated in adults under controlled conditions. [38] Among critically-ill children, the effects of patient factors and other co-administered medications are expected to influence the time course of enzyme induction response, though the relationship is not clear. Inducers were included in our model if they had been administered at least 48 hours prior to obtaining a fentanyl level, though our study was not designed to parse out the magnitude of effect related to preceding duration of inducer administration. Using simulation, we demonstrated that steady state levels of fentanyl are significantly lower in the presence of CYP3A4/5 inducers. Interestingly, the difference in median concentrations between patients with or without concomitant use of CYP3A4/5 inducers was more pronounced once the infusion was terminated as compared during steady state (Figure 3A). After the termination of the infusion, the distribution phase half-life (α half-life) and terminal phase half-life (β half-life) in the presence CYP3A4/5 inducers decreased by 29% and 8%, respectively, as compared to when there were no

concomitantly administered CYP3A4/5 inducers. This suggests that the pronounced change in concentrations after termination of infusion was mainly driven by the fact that, in the presence of CYP3A4/5 inducers, fentanyl is being cleared from the central compartment more rapidly with less time to distribute to the peripheral compartment.

The clinical implication of these observations is that patients on CYP3A4/5 inducers may need higher doses and/or infusion rates of fentanyl to obtain desired drug effect. Also, clinicians interrupting fentanyl infusions during care should consider the faster rate at which fentanyl levels decrease in the presence of CYP3A4/5 inducers. Because of the high degree of interindividual variability, additional study with larger cohorts and more covariates is necessary to establish fentanyl PK models capable of providing pre-emptive guidance on dose adjustment in the setting of inducer initiation. That steady-state concentrations were observed to be lower in the presence of an inducer may be a clinically favorable effect in certain contexts. Reliably achieving a lower-steady state may be preferred in patients for whom the target is moderate analgesia with clear avoidance of respiratory depressant effects. Alternatively, a higher steady state may be preferred when using fentanyl to facilitate mechanical ventilation in a patient with severe lung disease and ventilator asynchrony, as the respiratory depressant effects may be desirable. More work is needed to clarify the magnitude of specific drug inducer effects in relation to fentanyl and to better understand the clinical implications of altered fentanyl hepatic metabolism as compared to hepatic extraction in the context of critical illness among children.

While greater knowledge of pharmacokinetics and pharmacodynamics of the myriad drugs in critically-ill children is needed, the dense sampling strategy required for traditional individual-level PK modeling is a significant barrier. Our approach to use population PK modeling aligns with the strategic initiative outlined in the National Academy of Medicine's report on learning healthcare systems.[39] Pairing electronic data with remnant biologic samples provides an effective, minimally invasive and cost-efficient approach to driving pharmacologic insights that would otherwise require substantial financial resources and potentially painful phlebotomy in a vulnerable population. Additional strengths of the current study include the relatively large cohort of children studied, the population PK model performance, and the introduction of relevant hepatic enzyme inducers as covariates.

While our cohort size constitutes the largest PK study of fentanyl in PICU patients, a notable limitation is that the present study is underpowered to identify associations with less common covariates, such as infrequently administered antibiotics that may interact with fentanyl and rare genotypes. Rifampin, for example, is a potent inducer of CYP3A4 but it is rarely administered and its effects on the hepatic metabolism of midazolam have been observed 2-4 weeks beyond discontinuation.[40,41] Our model also did not account for de-induction and this should be a focus of future studies. Other potentially influential covariates not included in the present model include age-dependent CYP enzyme maturation, protein-binding, BMI, enzyme and transporter function and related genotypes, hepatic disease, intraabdominal pressure, and vasopressor use, to name a few. This is likely reflected by the high unaccounted inter-individual variability in PK parameters. The unsuccessful inclusion of *CYP3A5* genotype in our model may be related to our relatively small cohort. In order to fully delineate the clinical significance of these covariates and better account for the

Author Manuscript

complex heterogeneity of critically-ill pediatric patients, additional PK studies of larger cohorts are necessary.

In conclusion, we successfully constructed a population PK model for fentanyl using sparse samples collected at random times, demonstrating both the feasibility and utility of this approach for better understanding drug properties among one of the most heterogeneous patient populations in modern medicine. This work, which made use of existing electronic data and remnant samples at our quaternary children's hospital, demonstrates a feasible and effective learning health system approach to characterizing drug parameters among critically ill children. Larger population PK studies of fentanyl will be useful for honing our administration of this potent opioid, serving an eventual goal of developing a framework for precision administration of sedative and analgesic medications to critically-ill children.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements:

References

1. Curley MAQ, Wypij D, Watson RS, Grant MJC, Asaro LA, Cheifetz IM, et al. Protocolized sedation vs usual care in pediatric patients mechanically ventilated for acute respiratory failure: a randomized clinical trial. JAMA. 2015;313:379–89. [PubMed: 25602358]

2. Sullivan KR, Cammarano WB, Wiener-Kronish JP. Analgesics, Tranquilizers, and Sedatives Card Intensive Care [Internet]. 2nd ed. Philadelphia, PA: Elsevier/Saunders; 2010 p. 504–15. Available from: https://www.clinicalkey.com/#!/content/book/3-s2.0-B9781416037736100412?scrollTo=%23hl0000403

3. Ziesenitz VC, Vaughns JD, Koch G, Mikus G, van den Anker JN. Pharmacokinetics of Fentanyl and Its Derivatives in Children: A Comprehensive Review. Clin Pharmacokinet. 2018;57:125–49. [PubMed: 28688027]

4. Van Driest SL, Marshall MD, Hachey B, Beck C, Crum K, Owen J, et al. Pragmatic pharmacology: population pharmacokinetic analysis of fentanyl using remnant samples from children after cardiac surgery. Br J Clin Pharmacol. 2016;81:1165–74. [PubMed: 26861166]

5. Peng PWH, Sandler AN. A Review of the Use of Fentanyl Analgesia in the Management of Acute Pain in Adults. Anesthesiol J Am Soc Anesthesiol. 1999;90:576–99.

6. Gourlay GK, Kowalski SR, Plummer JL, Cousins MJ, Armstrong PJ. Fentanyl Blood Concentration-Analgesic Response Relationship in the Treatment of Postoperative Pain. Anesth Analg. 1988;67:329. [PubMed: 3354866]

7. Katz R, Kelly HW. Pharmacokinetics of continuous infusions of fentanyl in critically ill children. Crit Care Med. 1993;21:995–1000. [PubMed: 8319480]

8. Frakes MA, Lord WR, Kociszewski C, Wedel SK. Efficacy of fentanyl analgesia for trauma in critical care transport. Am J Emerg Med. 2006;24:286–9. [PubMed: 16635698]

9. Ziesenitz VC, König SK, Mahlke NS, Skopp G, Haefeli WE, Mikus G. Pharmacokinetic interaction of intravenous fentanyl with ketoconazole. J Clin Pharmacol. 2015;55:708–17. [PubMed: 25651378]

10. Empey PE, Miller TM, Philbrick AH, Melick JA, Kochanek PM, Poloyac SM. Mild hypothermia decreases fentanyl and midazolam steady-state clearance in a rat model of cardiac arrest. Crit Care Med. 2012;40:1221–8. [PubMed: 22067624]

11. Keizer RJ, van Benten M, Beijnen JH, Schellens JHM, Huitema ADR. Piraña and PCluster: a modeling environment and cluster infrastructure for NONMEM. Comput Methods Programs Biomed. 2011;101:72–9. [PubMed: 20627442]

12. Lindbom L, Pihlgren P, Jonsson EN, Jonsson N. PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed. 2005;79:241–57. [PubMed: 16023764]

13. Jonsson EN, Karlsson MO. Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed. 1999;58:51–64. [PubMed: 10195646]

14. Choi L, Ferrell BA, Vasilevskis EE, Pandharipande PP, Heltsley R, Ely EW, et al. Population Pharmacokinetics of Fentanyl in the Critically Ill. Crit Care Med. 2016;44:64–72. [PubMed: 26491862]

15. Horvat C, Au A, Conley Y, Kochanek P, Li L, Poloyac S, et al. 880: ARDA2A AND CYP3A5 GENOTYPES ARE ASSOCIATED WITH FENTANYL REQUIREMENTS IN CRITICALLY ILL CHILDREN. Crit Care Med. 2018;46:424.

16. Singleton MA, Rosen JI, Fisher DM. Plasma concentrations of fentanyl in infants, children and adults. Can J Anaesth. 1987;34:152–5. [PubMed: 3829301]

17. Encinas E, Calvo R, Lukas JC, Vozmediano V, Rodriguez M, Suarez E. A predictive pharmacokinetic/pharmacodynamic model of fentanyl for analgesia/sedation in neonates based on a semi-physiologic approach. Paediatr Drugs. 2013;15:247–57. [PubMed: 23657896]

18. Koehntop DE, Rodman JH, Brundage DM, Hegland MG, Buckley JJ. Pharmacokinetics of fentanyl in neonates. Anesth Analg. 1986;65:227–32. [PubMed: 3954090]

19. Anderson BJ, Allegaert K. The pharmacology of anaesthetics in the neonate. Best Pract Res Clin Anaesthesiol. 2010;24:419–31. [PubMed: 21033017]

20. Ariano RE, Duke PC, Sitar DS. Population pharmacokinetics of fentanyl in healthy volunteers. J Clin Pharmacol. 2001;41:757–63. [PubMed: 11452708]

21. Friis-Hansen B Body composition during growth. In vivo measurements and biochemical data correlated to differential anatomical growth. Pediatrics. 1971;47:Suppl 2:264+.

22. Weber DR, Leonard MB, Zemel BS. Body Composition Analysis in the Pediatric Population. Pediatr Endocrinol Rev PER. 2012;10:130–9. [PubMed: 23469390]

23. Mulla H, Johnson TN. Dosing dilemmas in obese children. Arch Dis Child Educ Pract Ed. 2010;95:112–7. [PubMed: 20585055]

24. Bower S, Hull CJ. Comparative pharmacokinetics of fentanyl and alfentanil. Br J Anaesth. 1982;54:871–7. [PubMed: 6125162]

25. Ibrahim AE, Feldman J, Karim A, Kharasch ED. Simultaneous assessment of drug interactions with low- and high-extraction opioids: application to parecoxib effects on the pharmacokinetics and pharmacodynamics of fentanyl and alfentanil. Anesthesiology. 2003;98:853–61. [PubMed: 12657846]

26. Kuip EJM, Zandvliet ML, Koolen SLW, Mathijssen RHJ, van der Rijt CCD. A review of factors explaining variability in fentanyl pharmacokinetics; focus on implications for cancer patients. Br J Clin Pharmacol. 2017;83:294–313. [PubMed: 27619152]

27. Feierman DE, Lasker JM. Metabolism of fentanyl, a synthetic opioid analgesic, by human liver microsomes. Role of CYP3A4. Drug Metab Dispos Biol Fate Chem. 1996;24:932–9. [PubMed: 8886601]

28. Tateishi T, Krivoruk Y, Ueng YF, Wood AJ, Guengerich FP, Wood M. Identification of human liver cytochrome P-450 3A4 as the enzyme responsible for fentanyl and sufentanil N-dealkylation. Anesth Analg. 1996;82:167–72. [PubMed: 8712396]

29. Takashina Y, Naito T, Mino Y, Yagi T, Ohnishi K, Kawakami J. Impact of CYP3A5 and ABCB1 gene polymorphisms on fentanyl pharmacokinetics and clinical responses in cancer patients undergoing conversion to a transdermal system. Drug Metab Pharmacokinet. 2012;27:414–21. [PubMed: 22277678]

30. Zhou S- F. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab. 2008;9:310–22. [PubMed: 18473749]

31. Hukkanen J Induction of cytochrome P450 enzymes: a view on human in vivo findings. Expert Rev Clin Pharmacol. 2012;5:569–85. [PubMed: 23121279]

32. Burk O, Koch I, Raucy J, Hustert E, Eichelbaum M, Brockmöller J, et al. The induction of cytochrome P450 3A5 (CYP3A5) in the human liver and intestine is mediated by the xenobiotic sensors pregnane X receptor (PXR) and constitutively activated receptor (CAR). J Biol Chem. 2004;279:38379–85. [PubMed: 15252010]

33. Wortham M, Czerwinski M, He L, Parkinson A, Wan Y- JY. Expression of constitutive androstane receptor, hepatic nuclear factor 4 alpha, and P450 oxidoreductase genes determines interindividual variability in basal expression and activity of a broad scope of xenobiotic metabolism genes in the human liver. Drug Metab Dispos Biol Fate Chem. 2007;35:1700–10. [PubMed: 17576804]

34. Landay RA, Gonzalez MA, Taylor JC. Effect of phenobarbital on theophylline disposition. J Allergy Clin Immunol. 1978;62:27–9. [PubMed: 659737]

35. Dahlqvist R, Steiner E, Koike Y, von Bahr C, Lind M, Billing B. Induction of theophylline metabolism by pentobarbital. Ther Drug Monit. 1989;11:408–10. [PubMed: 2741188]

36. Wietholtz H, Zysset T, Kreiten K, Kohl D, Büchsel R, Matern S. Effect of phenytoin, carbamazepine, and valproic acid on caffeine metabolism. Eur J Clin Pharmacol. 1989;36:401–6. [PubMed: 2500346]

37. Miller M, Cosgriff J, Kwong T, Morken DA. Influence of phenytoin on theophylline clearance. Clin Pharmacol Ther. 1984;35:666–9. [PubMed: 6713777]

38. Ohnhaus EE, Breckenridge AM, Park BK. Urinary excretion of 6 beta-hydroxycortisol and the time course measurement of enzyme induction in man. Eur J Clin Pharmacol. 1989;36:39–46. [PubMed: 2917586]

39. Olsen L, Aisner D, McGinnis JM, Institute of Medicine (U.S.), editors. The learning healthcare system: workshop summary. Washington, DC: National Academies Press; 2007.

40. Brodie Martin J, Mintzer Scott, Pack Alison M, Gidal Barry E, Vecht Charles J, Schmidt Dieter. Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia. 2013;54:11–27.

41. Reitman ML, Chu X, Cai X, Yabut J, Venkatasubramanian R, Zajic S, et al. Rifampin's acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug-drug interaction trial design. Clin Pharmacol Ther. 2011;89:234–42. [PubMed: 21191377]

Figure 1.
Population (**A**) and Individual (**B**) predicted vs. observed concentration. Conditional weighted residual vs. (**C**) population predicted concentration and (**D**) time. CWRES, population conditional weighted residuals

Figure 2.
Standard visual predictive check for the final pharmacokinetic model. Black circles represent the observed data. The lines represent observed median, and upper (95th) and lower (5th) percentile concentrations. The shades regions represent the 95% CI for the simulated median, upper and lower concentrations.

Figure 3.
Simulated concentration-Time profile of fentanyl in the presence (dotted line) or absence (solid line) of CYP3A4/5 inducers **(A)**. The lines indicate the mean values while the shaded areas indicate 95% confidence intervals. **(B)** Box-plot comparing the distribution of Css (steady state concentration) values with or without coadministration of CYP3A4/5 inducers. Patients on inducers at the same time as fentanyl have significantly lower Css as compared to those not on inducers. Each of the fentanyl bolus doses were 1 μg/kg while infusion was administered at 1 μg/kg/hr.

Table 1.

Cohort characteristics

Demographics	Cohort (N=66)
Weight (kg), Median (Range)	20.1 (4.1-117.4)
Age (months), Median (Range)	78 (1–204)
Female	34 (52%)
Race	
White	57 (86%)
Black	7 (11%)
Other/Unknown	2 (3%)
Primary Diagnosis Category	
Neurologic	19 (29%)
Respiratory	16 (24%)
Sepsis	6 (9%)
Gastrointestinal/Transplant	6 (9%)
Other	19 (29%)
Mechanical Ventilation	61 (92%)
Neuromuscular Blockade	28 (42%)
Vasoactive Medication Infusion	25 (38%)
PICU Length of Stay (days), Median (Range)	8.4 (1.1–129)
Hospital Length of Stay (days), Median (Range)	15.5 (2.4–129.4)
Number of Samples per Patient, Median (Range)	4 (1–7)
Duration of Fentanyl Infusion (hours), Median (Range)	90.7 (11–254)
Number of Fentanyl Boluses per Patient, Median (Range)	25 (4–77)
Fentanyl Plasma Concentration (ng/mL), Median (Range)	2.29 (0.11–84.32)
Concomitant CYP3A Inducer/Inhibitor	
Fosphenytoin	13 (20%)
Fosphenytoin + Phenobarbital	2 (3%)
Fosphenytoin + Phenobarbital	2 (3%)
Phenobarbital	2 (3%)
Fluconazole	5 (8%)
Genotype	
CYP3A5, rs28365094, CT+CC	14(21%)

Table 2.

Population Pharmacokinetic Model Parameters

PK parameter		Point Estimates	%RSE	Bootstrap Median [95% CI]
Fixed				
CL= $\theta_1 \times (WT/70)^{0.75}$ $^*\theta_9^{INDU}$				
θ_1 (L h^{-1})		34.6	9.2	34.7 [27.7, 40.9]
θ_9		1.54	10.1	1.54 [1.2, 1.89]
V1= $\theta_2 \times (WT/70)^1$	θ_2 (L)	222	18.6	9.24 [3.72, 13.32]
Q= $\theta_3 \times (WT/70)^{0.75}$	θ_3 (L h^{-1})	8.58	18.9	9.24 [3.72, 13.32]
V2= $\theta_4 \times (WT/70)^1$	θ_4 (L)	311	13.1	332 [150, 472]
Interindividual Variability				
ω^2_{CL} (%CV)		0.37 (60.7%)	38.2	0.34 [0.07, 0.67]
ω^2_{V1} (%CV)		1.15 (107.2%)	43.1	1.15 [0.1, 2.2]
COV$_{CL-V1}$		0.63 (r=0.85)	41.3	0.55 [0.04, 1.22]
Residual Variability *				
Proportional (%CV)		52%	15.4	50.6% [43.3%, 59.7%]

*Residual Variability was additive in log scale. %CV was calculated by square root of variance x 100. INDU: CYP3A4/5 Inducer.